Volume : 13, Issue : 06, June – 2026

Title:

EVALUATION OF QUALITY OF LIFE IN DIABETIC PATIENTS WITH RESPIRATORY INFECTIONS EXPERIENCING STEROID INDUCED HYPERGLYCEMIA USING WHOQOL-BREF: A SYSTEMATIC LITERATURE REVIEW

Authors :

Afin A R*, Dr. Prasobh G R, Dr. Nithin Manohar R, Dr. Padmesh P.R,Athira R.B, Ariya Krishna R V, Gokul G

Abstract :

Respiratory infections remain a significant cause of morbidity and mortality among diabetic patients. Corticosteroids are commonly used in the management of respiratory diseases due to their anti-inflammatory effects; however, prolonged or high-dose steroid therapy can lead to Steroid Induced Hyperglycemia (SIH), especially in individuals with pre-existing diabetes mellitus. Steroid Induced Hyperglycemia adversely affects glycemic control, increases the risk of complications, prolongs hospitalization, and negatively impacts the Quality Of Life (QOL) of patients. The World Health Organization Quality of Life (WHOQOL) assessment tools provide a standardized method to evaluate physical, psychological, social and environmental domains of quality of life in diabetic patients. This systematic literature review focuses on evaluating the quality of life among diabetic patients with respiratory infections experiencing Steroid-Induced Hyperglycemia using WHOQOL assessment methods. The review highlights the prevalence of SIH, factors affecting quality of life, clinical consequences, and the role of healthcare professionals in improving patient outcomes.
KEYWORDS: Diabetes Mellitus, Respiratory Infections, Steroid-Induced Hyperglycemia, Quality of Life, WHOQOL-BREF

Cite This Article:

Please cite this article in press Afin A R et al., Silent Spillover: Evaluation Of Quality Of Life In Diabetic Patients With Respiratory Infections Experiencing Steroid Induced Hyperglycemia Using Whoqol-Bref: A Systematic Literature Review.., Indo Am. J. P. Sci, 2026; 13(06).

REFERENCES:

1. Breakey S, Sharp SJ, Adler AI, Challis BG. Glucocorticoid-induced hyperglycaemia in respiratory disease: a systematic review and meta-analysis. Diabetes Obes Metab. 2016;18(12):1274-1278.
2. Struja T, Nitritz N, Alexander I, Kupferschmid K, Hafner JF, Spagnuolo CC, et al. Treatment of glucocorticoid-induced hyperglycemia in hospitalized patients: a systematic review and meta-analysis. Cardiovasc Diabetol Endocrinol Rep. 2024;10(1):8.
3. Golubic R, Mumbole H, Ismail MH, Choo A, Baker O, Atha K, et al. Glucocorticoid treatment and new-onset hyperglycaemia and diabetes in people living with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Diabet Med. 2025;42(3):e15475.
4. Brooks D, Schulman-Rosenbaum R, Griff M, Lester J, Wang CCL. Glucocorticoid-induced hyperglycemia including dexamethasone-associated hyperglycemia in COVID-19 infection: a systematic review. Endocr Pract. 2022;28(11):1154-1165.
5. Abu-Ashour W, Twells L, Valcour J, Randell A, Donnan J, Howse P, et al. The association between diabetes mellitus and incident infections: a systematic review and meta-analysis of observational studies. BMJ Open Diabetes Res Care. 2017;5(1):e000336.
6. The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med. 1998;28(3):551-558.
7. Skevington SM, Lotfy M, O’Connell KA. The World Health Organization’s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. Qual Life Res. 2004;13(2):299-310.
8. Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev. 1999;15(3):205-218.
9. Wändell PE. Quality of life of patients with diabetes mellitus: an overview of research in primary health care in the Nordic countries. Scand J Prim Health Care. 2005;23(2):68-74.
10. Nicolucci A, Kovacs Burns K, Holt RIG, Comaschi M, Hermanns N, Ishii H, et al. Diabetes attitudes, wishes and needs second study (DAWN2™): cross-national benchmarking of diabetes-related psychosocial outcomes for people with diabetes. Diabet Med. 2013;30(7):767-777.
11. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract. 2009;15(5):469-474.
12. Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Minambres I, Gomez-Huelgas R. Glucocorticoid-induced hyperglycemia. J Diabetes. 2014;6(1):9-20.
13. Suh S, Park MK. Glucocorticoid-induced diabetes mellitus: an overlooked problem. Endocrinol Metab. 2017;32(2):180-189.
14. Geer EB, Islam J, Buettner C. Mechanisms of glucocorticoid-induced insulin resistance. Endocrinol Metab Clin North Am. 2014;43(1):75-102.
15. Singh AK, Singh R. Steroid-induced diabetes: prevalence and management. Diabetes Metab Syndr. 2020;14(5):1147-1151.
16. World Health Organization. WHOQOL-BREF introduction, administration, scoring and generic version of assessment. Geneva: WHO; 1996.
17. McBrien KA, Manns BJ, Chui B, et al. Health-related quality of life in diabetes. Can J Diabetes. 2013;37(1):44-50.
18. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med. 1996;334(13):835-840.
19. Cox DJ, Gonder-Frederick L, Ritterband L, et al. Blood glucose awareness training and quality of life in diabetes mellitus. Health Psychol. 2001;20(5):324-330.
20. Lee P, Greenfield JR, Campbell LV. Management of corticosteroid-induced hyperglycemia. Intern Med J. 2012;42(7):740-744.